经皮微波消融治疗cT1a肾细胞癌后即刻行增强CT:优化肿瘤学结局
本研究纳入347例cT1a肾细胞癌患者,比较冷冻消融、射频消融与微波消融,并在术中发现残留肿瘤时行同次重复消融;微波消融联合同次重复消融的原发有效率高于射频消融和冷冻消融(99.4% vs 91.4% vs 92.8%,p=0.001),多因素线性回归显示微波消融和同次重复消融与原发有效率较高相关(p=0.01-0.03)。
要点
- 微波消融组原发有效率为99.4%(170/171),高于射频消融组91.4%(85/93)和冷冻消融组92.8%(77/83),p=0.001。
- 术中增强CT发现残留肿瘤时行同次重复消融,多因素线性回归显示其与原发有效率较高相关(p=0.01-0.03)。
- 微波消融组肿瘤中位直径更小(2.5 vs 2.7 vs 2.6,p=0.03),RENAL肾测量评分更低(6 vs 7 vs 7,p=0.009)。
核心结论
- 微波消融联合同次重复消融(术中增强CT发现残留肿瘤时)可能提高cT1a肾细胞癌的原发有效率。
研究设计与样本
- 研究纳入347例连续cT1a肾细胞癌患者(231例男性,平均年龄67.5±9.1岁),2003年10月至2017年12月行冷冻消融,2010年1月至2017年12月行射频消融或微波消融;术中增强CT发现残留肿瘤时行同次重复消融;采用Kruskal-Wallis检验和Pearson卡方检验比较连续变量和分类变量,多因素线性回归分析原发有效率和估算肾小球滤过率下降的预测因素。
诊断标准与关键数值
- 原发有效率定义为第一次消融 session 后首次影像随访确认的肿瘤完全 eradicated;微波消融组99.4%(170/171) vs 射频消融组91.4%(85/93) vs 冷冻消融组92.8%(77/83),p=0.001。
- 微波消融组肿瘤中位直径2.5 vs 射频消融组2.7 vs 冷冻消融组2.6(p=0.03);微波消融组RENAL肾测量评分6 vs 射频消融组7 vs 冷冻消融组7(p=0.009)。
- 多因素线性回归显示微波消融和同次重复消融与原发有效率较高相关(p=0.01-0.03)。
临床应用与阅片要点
- 术中增强CT可用于发现消融后残留肿瘤,并据此行同次重复消融。
- 作者认为,微波消融联合同次重复消融可能提高cT1a肾细胞癌的原发有效率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effect of intra-procedural contrast-enhanced CT (CECT) and same-session repeat ablation (SSRA) on primary efficacy, the complete eradication of tumor after the first ablation session as confirmed on first imaging follow-up, of clinically localized T1a (cT1a) renal cell carcinoma (RCC).
METHODS: 398 consecutive patients with cT1a RCC were treated with cryoablation between 10/2003 and 12/2017, radiofrequency (RFA) or microwave ablation (MWA) between 1/2010 and 12/2017. SSRA was performed for residual tumor identified on intra-procedural CECT. Kruskal-Wallis and Pearson's chi-squared tests were performed to assess differences in continuous and categorical variables, respectively. Multivariate linear regression was used to determine predictors for primary efficacy and decline in estimated glomerular filtration rate.
RESULTS: 347 consecutive patients (231 M, mean age 67.5 ± 9.1 years) were included. Median tumor diameter was smaller [2.5 vs 2.7 vs 2.6 (p = 0.03)] and RENAL Nephrometry Score (NS) was lower [6 vs 7 vs 7 (p = 0.009] for MWA compared to the RFA and cryoablation cohorts, respectively. Primary efficacy was higher in the MWA cohort [99.4% (170/171)] compared to the RFA [91.4% (85/93)] and cryoablation [92.8% (77/83)] cohorts (p = 0.001). Microwave ablation and SSRA was associated with higher primary efficacy on multivariate linear regression (p = 0.01-0.03).
CONCLUSION: MWA augmented by SSRA, when residual tumor is identified on intra-procedural CECT, may improve primary efficacy for cT1a RCC.
引用
- Koebe, Curci, Caoili, et al. Contrast-enhanced CT immediately following percutaneous microwave ablation of cT1a renal cell carcinoma: Optimizing cancer outcomes. Abdom Radiol (NY). 2022. PMID: 35278110. doi:10.1007/s00261-022-03481-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。